6533b828fe1ef96bd1287870

RESEARCH PRODUCT

6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer

Tommy FornanderAnna L.v. JohanssonLj EssermanAdina IftimiBo NordenskjöldChristopher C. BenzChristina YauLinda S. LindströmOlle StålGizeh Pérez-tenorioHuma DarA. Nordensköljd

subject

Oncologymedicine.medical_specialtyBreast cancerOncologybusiness.industryInternal medicineHER2 negativemedicineTamoxifen therapyHematologyLymph node negativemedicine.diseasebusinesshttps://doi.org/10.1016/j.annonc.2021.03.020